| Product Code: ETC11530849 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Companion Diagnostics for Oncology Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Companion Diagnostics for Oncology Market - Industry Life Cycle |
3.4 Philippines Companion Diagnostics for Oncology Market - Porter's Five Forces |
3.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume Share, By Diagnostic Type, 2021 & 2031F |
3.6 Philippines Companion Diagnostics for Oncology Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.7 Philippines Companion Diagnostics for Oncology Market Revenues & Volume Share, By Sample Type, 2021 & 2031F |
3.8 Philippines Companion Diagnostics for Oncology Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Philippines Companion Diagnostics for Oncology Market Revenues & Volume Share, By Technology, 2021 & 2031F |
4 Philippines Companion Diagnostics for Oncology Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer cases in the Philippines |
4.2.2 Growing adoption of personalized medicine in oncology treatment |
4.2.3 Government initiatives to improve healthcare infrastructure and access to advanced diagnostics |
4.3 Market Restraints |
4.3.1 Lack of awareness and education about companion diagnostics among healthcare providers and patients |
4.3.2 High cost associated with companion diagnostics testing |
4.3.3 Regulatory challenges and approval process for companion diagnostics in the Philippines |
5 Philippines Companion Diagnostics for Oncology Market Trends |
6 Philippines Companion Diagnostics for Oncology Market, By Types |
6.1 Philippines Companion Diagnostics for Oncology Market, By Diagnostic Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Type, 2021 - 2031F |
6.1.3 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Molecular Diagnostics, 2021 - 2031F |
6.1.4 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Immunodiagnostics, 2021 - 2031F |
6.1.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Genetic Testing, 2021 - 2031F |
6.1.6 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Imaging-Based Diagnostics, 2021 - 2031F |
6.2 Philippines Companion Diagnostics for Oncology Market, By Cancer Type |
6.2.1 Overview and Analysis |
6.2.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Lung Cancer, 2021 - 2031F |
6.2.3 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.2.4 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.2.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Prostate Cancer, 2021 - 2031F |
6.3 Philippines Companion Diagnostics for Oncology Market, By Sample Type |
6.3.1 Overview and Analysis |
6.3.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Blood, 2021 - 2031F |
6.3.3 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Tissue, 2021 - 2031F |
6.3.4 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Saliva, 2021 - 2031F |
6.3.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Urine, 2021 - 2031F |
6.4 Philippines Companion Diagnostics for Oncology Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
6.4.4 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.4.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Pharmaceuticals, 2021 - 2031F |
6.5 Philippines Companion Diagnostics for Oncology Market, By Technology |
6.5.1 Overview and Analysis |
6.5.2 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By PCR-Based, 2021 - 2031F |
6.5.3 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By ELISA, 2021 - 2031F |
6.5.4 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By Microfluidics, 2021 - 2031F |
6.5.5 Philippines Companion Diagnostics for Oncology Market Revenues & Volume, By AI-Based Analysis, 2021 - 2031F |
7 Philippines Companion Diagnostics for Oncology Market Import-Export Trade Statistics |
7.1 Philippines Companion Diagnostics for Oncology Market Export to Major Countries |
7.2 Philippines Companion Diagnostics for Oncology Market Imports from Major Countries |
8 Philippines Companion Diagnostics for Oncology Market Key Performance Indicators |
8.1 Number of partnerships between companion diagnostics companies and oncology clinics/hospitals in the Philippines |
8.2 Adoption rate of companion diagnostics in oncology treatment protocols |
8.3 Number of clinical trials incorporating companion diagnostics in oncology research and treatment plans |
9 Philippines Companion Diagnostics for Oncology Market - Opportunity Assessment |
9.1 Philippines Companion Diagnostics for Oncology Market Opportunity Assessment, By Diagnostic Type, 2021 & 2031F |
9.2 Philippines Companion Diagnostics for Oncology Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.3 Philippines Companion Diagnostics for Oncology Market Opportunity Assessment, By Sample Type, 2021 & 2031F |
9.4 Philippines Companion Diagnostics for Oncology Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Philippines Companion Diagnostics for Oncology Market Opportunity Assessment, By Technology, 2021 & 2031F |
10 Philippines Companion Diagnostics for Oncology Market - Competitive Landscape |
10.1 Philippines Companion Diagnostics for Oncology Market Revenue Share, By Companies, 2024 |
10.2 Philippines Companion Diagnostics for Oncology Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here